Are there differences between various statins?;GIBT ES UNTERSCHIEDE ZWISCHEN VERSCHIEDENEN STATINEN?

Internist

Volumn 39, Issue 9, 1998, Pages 987-993

  Otto, C ^a   Schwandt, P ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; OXIDOREDUCTASE; PRAVASTATIN; SIMVASTATIN; STATINE;

ARTICLE; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG EFFICACY; GERMANY; HUMAN; HYPERCHOLESTEROLEMIA;

EID: 0031664046     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050066     Document Type: Article

References (42)

1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM for the AFCAPS/TexCAPS Research Group (1998) Primary Prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279:1615-1622
2. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM (1996) Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275:128-133
3. Bertolini S, Bittolo Bon G, Campbell LM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, Nawrocki JW (1997) Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 130:191-197
4. Bischoff H, Angerbauer R, Bender J, Bischoff E, Faggiotto A, Petzinna D, Pfitzner J, Porter MC, Schmidt D, Thomas G (1997) Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 135:119-130
5. Blum CB (1994) Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 73:3D-11D
6. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D (1997) A multicenter double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 80:39-44
7. Davidson M, McKennedy J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D for the Atrovastatin Study Group I (1997) Comparison of one-year efficacy and sefety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 79:1475-1481
8. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM jr, Mantell G for the Simvastatin and Lovastatin Multicenter Study Participants (1992) Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther 14:708-717
9. Garnett WR (1996) A review of current clinical findings with fluvastatin. Am J Cardiol 78:20A-25A
10. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD (1998) Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 97:946-952
11. Herd JA, Ballatyne CM, Farmer JA, Ferguson JJ, Jones PH, West MS, Gould KL, Gotto AM for the LCAS Investigators (1997) Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80:278-286
12. Hsu I, Spinler SA, Johnson NE (1995) Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 29:743-759
13. Illingworth DR, Bacon S, Pappu AS, Sexton GJ (1992) Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholestesterolemia. Atherosclerosis 96:53-64
14. Insull W, Stein E, Whalen E (1997) Cerivastatin, a new potent HMG-CoA reductase inhibitor: efficacy and tolerability in primary hypercholesterolemia [abstract]. J Am Coll Cardiol 29:46A
15. Jacotot B, Benghozi R, Pfister P, Holmes D, on behalf of the French Fluvastatin Study Group (1995) Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 76:54A-56A
16. Jay RH, Rampling MW, Betteridge DJ (1990) Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Atherosclerosis 85:249-256
17. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterofemia (The CURVES Study). Am J Cardiol 81:582-587
18. Koppensteiner R, Minar E, Ehringer H (1990) Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 83:53-58
19. Lea AP, McTavish D (1997) Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53:828-847
20. Lintott CJ, Scott RS, Sutherland WHF, Bremer J (1993) Treating hypercholesterolemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Aust N Z J Med 23:381-386
21. Tonkin E (1997) Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) (1997). Oral Presentation at the 70th American Heart Association Scientific Sessions, Orlando, FL, USA, New Engl J Med
22. Malini PL, Ambrosioni E, deDivitiis O, diSomma S, Rosiello G, Trimarco B (1991) Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia. Clin Ther 13:500-510
23. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J (1997) Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:1527-1531
24. McClellan KJ, Wiseman LR, McTavish D (1998) Cerivastatin. Drugs 55:415-420
25. McDowell IFW, Smye M, Trinick T, Shortt JA, Archibald MP, Trimble ER, Nicholls DP (1991) Simvastatin in severe hypercholesterolaemia: a placebo controlled trial. Br J Clin Pharmacol 31:340-343
26. McPherson R, Bedard J, Connelly P, Curnew G, Davignon J, Echenberg D, et al. (1992) Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 14:276-291
27. Milani M, Cimminiello C, Merlo B, Lorena M, Arpaia G, Bonfardeci G (1995) Effects of fluvastatin and pravastatin on lipid profile and thromboxane production in type II a hypercholesterolemia. Am J Cardiol 76:51A-53A
28. Richter WO, Schwandt P (1995) Medikamentöse Therapie von Fettstoffwechselstörungen. In: Schwandt P, Richter WO (Hrsg) Handbuch der Fettstoffwechselstörungen. Pathophysiologie, Diagnostik,Therapie und Prävention der Dyslipoproteinämien, Schattauer Verlag, Stuttgart New York
29. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009
30. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
31. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307
32. Simvastatin Pravastatin European Study Group (1994) Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology 85:244-254
33. Stalenhoef AFH, Lansberg PJ, Kroon AA, Kortmann B, deHaan AFJ, Stuyt PMJ, et al. (1993) Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. J Intern Med 234:77-82
34. The European Study Group (1992) Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). Am J Cardiol 70:1281-1286
35. The Lovastatin Pravastatin Study Group (1993) A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 71:810-815
36. The Simvastatin Pravastatin Study Group (1993) Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 71:1408-1414
37. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N (1996) Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 122:225-233
38. Vaughan CJ, Murphy MB, Buckley BM (1996) Statins do more than just lower cholesterol. Lancet 348:1079-1082
39. Watts GF, Burke V, Lewis B (1997) Plasma low density lipoprotein-cholesterol levels and progression/regression of coronary atherosclerosis: a meta-regression analysis of angiographic trials. Br J Cardiol 4:64-70
40. Weir MR, Berger ML, Weels ML, Liss CL, Santanello NC (1996) Comparison of the effects of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. Am J Cardiol 77:475-479
41. Wierzbicki AS, Lumb PJ, Semra YK, Crool MA (1998) Effect of atorvastatin on plasma fibrinogen. Lancet 351:569-570
42. Yoshino G, Kazumi T, Matsushita M, Iwai M, Matsuba K, Morita M, et al. (1990) Comparison of the effects of pravastatin and simvastatin in hypercholesterolemic subjects. Curr Ther Res 48:259-267